NZ596713A - Sitagliptin synthesis - Google Patents

Sitagliptin synthesis

Info

Publication number
NZ596713A
NZ596713A NZ596713A NZ59671310A NZ596713A NZ 596713 A NZ596713 A NZ 596713A NZ 596713 A NZ596713 A NZ 596713A NZ 59671310 A NZ59671310 A NZ 59671310A NZ 596713 A NZ596713 A NZ 596713A
Authority
NZ
New Zealand
Prior art keywords
amino
butanoate
trifluorophenyl
derivative
enantiomerically enriched
Prior art date
Application number
NZ596713A
Other languages
English (en)
Inventor
Maheshkumar Gadakar
Priyanka Bhosle
Suresh Shinde
Vinayak Govind Gore
Original Assignee
Generics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics Uk Ltd filed Critical Generics Uk Ltd
Publication of NZ596713A publication Critical patent/NZ596713A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ596713A 2009-05-11 2010-05-10 Sitagliptin synthesis NZ596713A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN722KO2009 2009-05-11
PCT/GB2010/050760 WO2010131025A1 (en) 2009-05-11 2010-05-10 Sitagliptin synthesis

Publications (1)

Publication Number Publication Date
NZ596713A true NZ596713A (en) 2014-10-31

Family

ID=42312921

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ596713A NZ596713A (en) 2009-05-11 2010-05-10 Sitagliptin synthesis

Country Status (8)

Country Link
US (1) US8846916B2 (enExample)
EP (1) EP2430025A1 (enExample)
JP (2) JP6199556B2 (enExample)
CN (1) CN102574856B (enExample)
AU (1) AU2010247193B2 (enExample)
CA (1) CA2759077C (enExample)
NZ (1) NZ596713A (enExample)
WO (1) WO2010131025A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
CN102757431B (zh) * 2011-04-24 2016-03-30 浙江华海药业股份有限公司 一种合成西他列汀的新方法
CA2840814A1 (en) 2011-06-29 2013-01-03 Ranbaxy Laboratories Limited Solid dispersions of sitagliptin and processes for their preparation
US20150051213A1 (en) 2011-06-30 2015-02-19 Suresh Babu Jayachandra Novel salts of sitagliptin
WO2013013833A1 (en) 2011-07-27 2013-01-31 Farma Grs, D.O.O. Process for the preparation of sitagliptin and its pharmaceutically acceptable salts
CN102603749B (zh) * 2011-10-27 2017-02-08 浙江华海药业股份有限公司 一种西他列汀中间体的合成方法
EP2788352A1 (en) 2011-12-08 2014-10-15 Ranbaxy Laboratories Limited Amorphous form of sitagliptin salts
CN102531937A (zh) * 2011-12-31 2012-07-04 浙江工业大学 一种化学拆分法制备(r)-3-氨基-4-(2,4,5-三氟苯基)丁酸甲酯的方法
WO2013114173A1 (en) * 2012-01-30 2013-08-08 Smilax Laboratories Limited A novel process for the preparation of sitagliptin
CN102702205B (zh) * 2012-05-16 2014-01-15 苏州新凯生物医药技术有限公司 西他列汀的制备方法
EP2674432A1 (en) 2012-06-14 2013-12-18 LEK Pharmaceuticals d.d. New synthetic route for the preparation of ß aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha]pyrazin-7-yl compounds
KR102157917B1 (ko) * 2012-12-21 2020-09-21 레크 파마슈티칼스 디.디. 키랄 γ-아릴-β-아미노부티르산 유도체의 제조를 위한 효소 경로
IN2013MU00916A (enExample) * 2013-03-20 2015-06-26 Cadila Healthcare Ltd
CN103497145B (zh) * 2013-10-10 2016-01-27 南昌大学 一种光学纯多奈哌齐的制备工艺
IN2014MU00212A (enExample) * 2014-01-21 2015-08-28 Cadila Healthcare Ltd
CN104557944B (zh) * 2014-12-31 2017-05-31 北京瑞都医药科技有限公司 一种降糖药物及其制备方法
CN105331651B (zh) * 2015-11-25 2018-11-13 尚科生物医药（上海）有限公司 西他列汀及其中间体的酶-化学制备方法
CN105294479B (zh) * 2015-12-05 2017-09-22 新发药业有限公司 一种3r‑氨基取代丁酰胺衍生物的制备方法
JP6049923B1 (ja) 2016-02-18 2016-12-21 三菱日立パワーシステムズ株式会社 部品情報検索装置、部品情報検索方法、およびプログラム
CN107129501B (zh) * 2017-05-19 2019-05-21 贵州大学 2型糖尿病药物西他列汀制备新方法
CN107669683B (zh) * 2017-09-30 2020-07-03 杭州华东医药集团新药研究院有限公司 含有西格列汀与二甲双胍的药物组合物
CN108586346B (zh) 2018-05-10 2019-10-01 北京富盛嘉华医药科技有限公司 一种生物催化合成西他列汀及其中间体的方法
CN110759914A (zh) * 2019-02-03 2020-02-07 美华东进国际生物医药研究院有限公司 一种治疗糖尿病的药物的制备方法
CN112300017B (zh) * 2019-08-01 2023-06-09 浙江九洲药业股份有限公司 一种手性β-氨基酸及其衍生物的消旋制备方法
CN112341332B (zh) * 2020-11-11 2023-04-28 浙江昌明药业有限公司 一种西他列汀关键中间体降解废弃物的回收利用方法
CN114644568B (zh) * 2020-12-21 2024-07-19 浙江医药股份有限公司新昌制药厂 西格列汀中间体的纯化方法
CN113045448A (zh) * 2021-03-09 2021-06-29 台州市生物医化产业研究院有限公司 一种乙酰麦氏酸衍生物降解废弃物的回收利用方法
CN115583935A (zh) * 2022-11-03 2023-01-10 浙江工业大学 一种4-(2,4,5-三氟苯基)-3-氧丁酸酯的制备方法
EP4630568A1 (en) 2022-12-09 2025-10-15 KRKA, D.D., Novo Mesto Process for the preparation of sitagliptin
CN115819258B (zh) * 2022-12-13 2024-10-18 浙江大学 一种利用含膦氧双键催化剂的西格列汀中间体的制备方法
CN115960007B (zh) * 2022-12-13 2025-02-07 浙江大学 一种利用含氮甲酰基催化剂的西格列汀中间体的制备方法
CN117069604A (zh) * 2023-08-22 2023-11-17 河北龙海药业有限公司 一种磷酸西格列汀杂质fp-e的制备方法及其检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AR043515A1 (es) 2003-03-19 2005-08-03 Merck & Co Inc Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
WO2004085661A2 (en) 2003-03-24 2004-10-07 Merck & Co., Inc Process to chiral beta-amino acid derivatives
WO2004087650A2 (en) 2003-03-27 2004-10-14 Merck & Co. Inc. Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
US20060287528A1 (en) 2003-09-02 2006-12-21 Wenslow Robert M Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005030127A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
EP1796671A4 (en) 2004-09-15 2009-01-21 Merck & Co Inc AMORPHIC FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL-PEPTIDASE IV HEMMER
WO2006065826A2 (en) * 2004-12-15 2006-06-22 Merck & Co., Inc. Process to chiral beta amino acid derivatives by asymmetric hydrogenation
US8334385B2 (en) * 2007-11-02 2012-12-18 Glenmark Generics Limited Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof
WO2009064476A1 (en) 2007-11-13 2009-05-22 Teva Pharmaceutical Industries Ltd. Preparation of sitagliptin intermediate
KR20100101073A (ko) 2007-12-20 2010-09-16 닥터 레디스 레보러터리즈 리미티드 시타글립틴 및 약제학적으로 허용되는 그의 염의 제조 방법
US20090247532A1 (en) 2008-03-28 2009-10-01 Mae De Ltd. Crystalline polymorph of sitagliptin phosphate and its preparation
CN101633625B (zh) 2008-07-23 2013-02-13 江苏恒瑞医药股份有限公司 R-β-氨基苯丁酸衍生物的制备方法
WO2010032264A2 (en) 2008-08-27 2010-03-25 Cadila Healthcare Limited Improved process for preparation of (2r)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin- 7(8h)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine & new impurities in preparation thereof
WO2010078440A1 (en) * 2008-12-31 2010-07-08 Chiral Quest, Inc. Process and intermediates for the preparation of n-acylated-4-aryl beta-amino acid derivatives
WO2010131035A1 (en) 2009-05-11 2010-11-18 Generics [Uk] Limited Novel crystalline polymorph of sitagliptin dihydrogen phosphate
CN101928289A (zh) * 2009-06-19 2010-12-29 北京海步国际医药科技发展有限公司 制备二肽基肽酶-iv抑制剂的方法

Also Published As

Publication number Publication date
JP2016029051A (ja) 2016-03-03
JP6199556B2 (ja) 2017-09-20
AU2010247193A1 (en) 2011-12-08
US8846916B2 (en) 2014-09-30
CN102574856A (zh) 2012-07-11
EP2430025A1 (en) 2012-03-21
US20120108598A1 (en) 2012-05-03
AU2010247193B2 (en) 2016-05-19
JP2012526791A (ja) 2012-11-01
CA2759077A1 (en) 2010-11-18
WO2010131025A1 (en) 2010-11-18
CN102574856B (zh) 2016-09-21
CA2759077C (en) 2016-02-16

Similar Documents

Publication Publication Date Title
NZ596713A (en) Sitagliptin synthesis
MY147871A (en) Chemical process for preparation of aromatic cyclopropane esters and amides
JP2010043124A5 (enExample)
NZ739757A (en) Processes for preparing jak inhibitors and related intermediate compounds
NO20081234L (no) Nye 6-amino-morfinanderivater, fremgangsmater for fremstilling derav og anvendelse derav for smertestillende midler
AR059296A1 (es) Compuesto de l-tartrato de s-zopiclona y proceso para resolver los enantiomeros de zopiclona.
MX2010012698A (es) Proceso para la hidrolisis enzimatica estereoselectiva del ester del acido 5-metil-3-nitro-metil-hexanoico.
ATE453622T1 (de) Verfahren zur herstellung von enantiomeren angereicherten cyclischen beta-aryl- oder heteroarylcarbonsäuren
CN102285984A (zh) (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2003003804A3 (en) Process for the production of optically active 3-phenylisoserine
HRP20200437T1 (hr) Proces za pripremu enantiomerom obogaćenog 3-aminopiperidina
WO2012093411A3 (en) Process for the preparation of r-(-)-3- (carbamoylmethyl)-5-methylhexanoic acid and the intermediates
WO2009122303A3 (en) Novel mandelate salt of fesoterodine
TW200722415A (en) New process
IL190399A (en) METHOD FOR PREPARING SQUARE ACID AND @ AMONIUM SALTS
IN2012DN06281A (enExample)
ATE555093T1 (de) Verfahren zur herstellung einer (s)-1-alkyl-2i,6i-pipecoloxylididverbindung
CA3030817C (fr) Procede de dedoublement de sels de baclofene
TW200700369A (en) Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation field of the invention
WO2012070896A3 (en) Synthetic method of enantiomerically pure 2,2'-dihydroxy-1,1'-binaphthyl-3-carboxylic acid
PL1964838T3 (pl) Sposób rozdzielania tiolaktonu homocysteiny
KR101823971B1 (ko) Ｌ-카르니틴의 제조 방법
WO2011076915A8 (en) Novel method for the preparation of (s)-pregabalin
MX2019015095A (es) Metodo de sintesis para producir compuestos de cis-imidazolina enantiomericamente puros para uso farmaceutico.
PH12013500256A1 (en) Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 MAY 2017 BY DENNEMEYER + CO.

Effective date: 20150512

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2018 BY RENEWALS TEAM

Effective date: 20170503

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2019 BY RENEWALS TEAM

Effective date: 20180428

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2020 BY RENEWALS TEAM

Effective date: 20190415

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2021 BY ENVOY

Effective date: 20200504

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2022 BY IPAN GMBH

Effective date: 20210427

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2023 BY IPAN GMBH

Effective date: 20220426

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2024 BY IPAN GMBH

Effective date: 20230426

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2025 BY IPAN GMBH

Effective date: 20240426

ASS Change of ownership

Owner name: TIANISH LABORATORIES PRIVATE LIMITED, IN

Effective date: 20250417

LAPS Patent lapsed